Could stem cells offer a viable treatment for retinopathy?

Diabetes is a growing global epidemic, with over 400 million affected and cases expected to double in the next 10 years. Retinopathy, or damage to the blood vessels in the retina, occurs in most patients with type 1 diabetes and 75 per cent of patients with type 2 diabetes, leading to vision loss for many. BetaStem Therapeutics is a stem cell therapy company led by Dr Stephen Bartelmez. Their aim is to treat diabetic retinopathy by using the body’s own stem cells to repair the damage to retinal blood vessels caused by diabetes.

The macula is a part of the retina, located at the back of the eye. Although very small (about 5mm in diameter), it is responsible for most aspects of our vision, including colour vision and the fine detail of what we see. Diabetic macular oedema is a swelling of the retina as a result of fluid leakage from damaged blood vessels within the macula caused by the diabetes. In addition, macular ischemia (inadequate blood supply) can eventually result in diabetic retinopathy (DR), or damage to the blood vessels at the back of the eyes. DR is one of the leading causes of blindness in adults, and currently there is no effective treatment to repair cells and blood vessels damaged as a result of the disease.

In healthy people, blood vessels are constantly regenerated by cells derived from circulating CD34+ stem cells. These stem cells are generated in the bone marrow and released into the bloodstream and express the protein CD34+ on their surface. They divide and mature into all nine types of blood cells plus give rise to another cell type, endothelial cells, the building blocks of all blood vessels. The stem cells and endothelial cells migrate to lesions on blood vessels and facilitate repair. However, during the course of diabetes, the patient’s CD34+ stem cells become dysfunctional: they can no longer give rise to endothelial cells or regulate repair of damaged blood vessels, both in the retina, and in the rest of the body.

STEM CELLS AND TRANSFORMING GROWTH FACTOR BETA 1

All blood cells are derived from haematopoietic stem cells in a process known as haematopoiesis. This takes place in the bone marrow, and in a healthy adult, approximately 50 to 70 billion new blood cells of nine different types are produced each day. To generate all these cells requires a complex series of events involving many positive and negative signals from the surrounding tissue as well as within the stem cells themselves.

Transforming Growth Factor beta 1 (TGF-β1) is a small protein secreted by many cells in the body. Classified as a cytokine (a type of small protein important in cell signalling in blood and immune cells), Dr Bartelmez and colleagues found that TGF-β1 is a major regulator of haematopoiesis. TGF-β1 finely inhibits cellular divisions at major cellular checkpoints. Their work has helped elucidate the key roles of TGF-β1 in stem cells in human blood and bone marrow.

TGF-β1 CONTROLS ALL STAGES OF HAEMATOPOIESIS

Using blood samples taken from mice as well as humans, the scientists were able to separate CD34+ stem cells from other blood cells present and grow them in the lab. Next, by treating the cells ex vivo with an antisense phosphorodiamidate morpholino oligomer (PMO) the scientists could inhibit TGF-β1 for a short period of time in the stem cells. A PMO is a small DNA analogue which temporarily blocks the stem cells from making a targeted protein. The scientists studied different techniques to deliver PMO into cells which included syringe loading, micro injection, and by combining the PMO with fat molecules containing a positive charge, known as cationic lipids. However, the best method for uptake of TGF-β1-PMO into stem cells was found to be unassisted entry. Thus CD34+ stem cells were incubated with the PMOs overnight at 37 degrees Celsius during which time the TGF-β1-PMO was taken up by endosomes on the surface of the stem cells. The temperature of the incubation as well as the concentration of the PMO was found to be important.

This technique actually transiently inhibits the TGF-β1 in the CD34+ stem cells. It acts as a switch to first inhibit the TGF-β1 then the stem cell reacts to this inhibition by upregulating the TGF-β1 gene mRNA -TGF-β1. Next, the PMO is effluxed from the stem cell causing a burst of TGF-β1 protein production.
The protein was found to have many functions. These include the ability to: stimulate or prevent cells from dividing, promote cells to self-destruct or differentiate (change to another cell type); or prevent these molecular pathways from occurring. One key finding was that transient TGF-β1 inhibition induces a balance between CD34+ cell growth, division, maturation, and periods of cell inactivity.

In humans, Dr Bartelmez identified three markers of enhanced stem cell activity that increase after PMO treatment of stem cells: 1) increased levels of CXCR4, a protein necessary for stem cell homing and adhesion; 2) increased Nitric oxide production, which is required for cell mobility; and 3) increased ability of CD34+ cells to migrate and repair vascular lesions.

The group also studied how long-term CD34+ haematopoietic stem cells were able to regenerate and repopulate the bone marrow in mice after inhibition of TGF-β1. They found that after lethal irradiation, they were able to use as few as sixty of these cells to rescue mice from death (>20,000 untreated stem cells) with PMO. This process rehabilitates the CD34+ stem cells for 16 hours ex vivo with PMO. This process re-populates hematopoietic stem cells. Moving forward they will further study TGF-β1 inhibition in diabetic patients for the first time in a clinical trial.

BetaStem Therapeutics is now preparing to test TGF-β1 inhibition in diabetic patients for the first time in a clinical trial. The next goal for the company will be to develop methods in the lab to study TGF-β1 in immunopoietic stem cells. Moving forward they will develop culture conditions in which cell division of latent stem cells is stimulated while their maturation and aging is prevented, in the presence of either TGF-β1-PMO or TGF-β1-inhibiting antibodies.

**References**


c


**Behind the Research**

**Dr Stephen Bartelmez**

2 Lower Crescent Ave Suite 2
Sausalito
CA 94965
USA

**Bio**

Stephen Bartelmez, PhD, is the founder of BetaStem Therapeutics. He completed his immunology training at UC Berkeley & University of Glasgow and his stem cell training at Einstein College of Medicine, NYC. Following this, he sailed to Australia to work with Ray Bradley PhD, the father of modern blood stem cell research. Dr Bartelmez is a former member of faculty at Hutchinson Cancer Research Center, U. of Washington, ViaCell Inc. He founded BetaStem Therapeutics Inc. in 2006.

**Funding**

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI), National Eye Institute (NEI) USA, and Stephen and Elizabeth Bartelmez

**Collaborators**

• Frank Ruscetti PhD
• Pat Iversen PhD
• Charlie Garcia MD
• Ewa Sitnicka PhD
• Carl Storey

**What are your aspirations for BetaStem Therapeutics as a company over the next five years?**

We previously have had a “pre-IND” meeting with the US-FDA in preparation to complete our IND to proceed with our first patient studies. With sufficient funding, our goal is to test the safety and efficacy in diabetic patients with retinopathy. Dr. Charlie Garcia (Ophthalmologist in Houston, TX) has been working with us for over four years and is helping design a clinical trial. He has been working with patients with diabetic retinopathy for more than 40 years. Currently, there are no effective treatments, making this an important unmet need. So far, the stem cells look promising.